A Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 9MW3011 in Patients With Non-transfusion-dependent β- Thalassemia
Latest Information Update: 20 Jan 2025
Price :
$35 *
At a glance
- Drugs 9MW 3011 (Primary)
- Indications Beta-thalassaemia
- Focus Adverse reactions
- Sponsors Mabwell (Shanghai) Bioscience
- 20 Jan 2025 New trial record